Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The goal of the clinical research study is to learn if treatment with a combination of three
drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to
control the disease in patients with previously untreated non-Hodgkin's lymphoma, CLL, or
bulky lymphoma. The safety of this treatment will also be studied.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Astex Pharmaceuticals Astex Pharmaceuticals, Inc. Pharmatech